Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria

Derma Techno Pakistan60 enrolled

Overview

This study aims to compare the effectiveness and safety of two commonly used antihistamines, bilastine 20 mg and levocetirizine 5 mg, in patients diagnosed with chronic urticaria. Chronic urticaria is a skin condition characterized by recurrent itchy wheals that significantly affect quality of life. Eligible participants will be randomly assigned to receive either bilastine or levocetirizine for a defined treatment period. The severity of symptoms, improvement in itching and wheals, and any adverse effects will be assessed during follow-up visits. The results of this study will help determine which treatment provides better symptom control with fewer side effects in patients with chronic urticaria.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Spontaneous Urticaria (CSU)

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosis of CSU as per operational definitions. * Patients already taking Bilastine 20 mg and still getting new lesions. * UAS7 score \>3 * Age range of 18-70 years * Both male and female patients Exclusion Criteria: * • women Patients who have already received treatment of CSU other than Bilastine. * Patients taking oral or topical corticosteroids * Pregnant or lactating * Patients with hereditary angioedema, atopic dermatitis, systemic immune disorders, collagen vascular diseases, immunocompromised status, Chronic liver or kidney failures

Outcomes

Primary Outcomes

change in urticaria severity score (UAS7)

change in urticaria severity score (UAS7) from baseline to 6 weeks UAS7 is a validated composite score assessing daily wheal number and pruritis severity over 7 consecutive days ,with total scores ranging from 0 to 42. Higher scores indicate more severe urticaria activity and a reduction in score reflects clinical improvement.

Time frame: baseline to 6 weeks